Restricted accessResearch articleFirst published online 2015-09
A Combination Therapy of 17β-Estradiol and Memantine Is More Neuroprotective Than Monotherapies in an Organotypic Brain Slice Culture Model of Traumatic Brain Injury
Combination therapies are a promising therapeutic option for traumatic brain injury (TBI) owing to the clinical failure of monotherapy treatments, such as progesterone. Organotypic hippocampal slice cultures (OHSCs) from Sprague-Dawley rats were subjected to an in vitro TBI, and the neuroprotective effects of 17β-estradiol (E2) or memantine (MEM) monotherapies were quantified. Several combination treatments at different concentrations of both drugs were tested, with 100 pM of E2 and 10 μM of MEM statistically and significantly reducing cell death over either monotherapy when administered immediately after injury. This combination was also significantly neuroprotective when administered 1 h postinjury, possibly supporting future in vivo studies. Further, we hypothesized that this synergy could be the result of MEM blocking a potentially deleterious effect of E2, specifically E2 enhancement of N-methyl-d-aspartate (NMDA) currents. Evoked electrophysiological responses in OHSCs were potentiated by E2 treatment, whereas this potentiation was significantly reduced by MEM. In conclusion, a combination therapy of E2 and memantine was significantly more neuroprotective than both monotherapy treatments, and this synergy may be the result of MEM blocking a deleterious E2-mediated enhancement of NMDA receptors.
Get full access to this article
View all access options for this article.
References
1.
MarguliesS., and HicksR. (2009). Combination therapies for traumatic brain injury: prospective considerations. J. Neurotrauma, 6, 925–939.
2.
MorettiL., CristoforiI., WeaverS.M., ChauA., PortelliJ.N., and GrafmanJ. (2012). Cognitive decline in older adults with a history of traumatic brain injury. Lancet Neurol., 12, 1103–1112.
3.
StoicaB.A., and FadenA.I. (2010). Cell death mechanisms and modulation in traumatic brain injury. Neurotherapeutics, 1, 3–12.
4.
LingsmaH.F., RoozenbeekB., LiB., LuJ., WeirJ., ButcherI., MarmarouA., MurrayG.D., MaasA.I., and SteyerbergE.W. (2011). Large between-center differences in outcome after moderate and severe traumatic brain injury in the international mission on prognosis and clinical trial design in traumatic brain injury (IMPACT) study. Neurosurgery, 3, 601–607; discussion, 607–608.
5.
MaasA.I., MarmarouA., MurrayG.D., TeasdaleS.G., and SteyerbergE.W. (2007). Prognosis and clinical trial design in traumatic brain injury: the IMPACT study. J. Neurotrauma, 2, 232–238.
6.
MaasA.I., SteyerbergE.W., MurrayG.D., BullockR., BaethmannA., MarshallL.F., and TeasdaleG.M. (1999). Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations. Neurosurgery, 6, 1286–1298.
ZivadinovicD., GametchuB., and WatsonC.S. (2005). Membrane estrogen receptor-alpha levels in MCF-7 breast cancer cells predict cAMP and proliferation responses. Breast Cancer Res., 1, R101–R112.
11.
BjornstromL., and SjobergM. (2004). Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl. Recept., 1, 3.
12.
BehlC., WidmannM., TrappT., and HolsboerF. (1995). 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun., 2, 473–482.
13.
NumakawaY., MatsumotoT., YokomakuD., TaguchiT., NikiE., HatanakaH., KunugiH., and NumakawaT. (2007). 17beta-estradiol protects cortical neurons against oxidative stress-induced cell death through reduction in the activity of mitogen-activated protein kinase and in the accumulation of intracellular calcium. Endocrinology, 2, 627–637.
14.
LiuS.B., and ZhaoM.G. (2013). Neuroprotective effect of estrogen: role of nonsynaptic NR2B-containing NMDA receptors. Brain Res. Bull.27–31.
15.
XiaM., YangS., SimpkinsJ.W., and LiuH. (2007). Noninvasive monitoring of estrogen effects against ischemic stroke in rats by near-infrared spectroscopy. Appl. Opt., 34, 8315–8321.
16.
SimpsonE.R., MissoM., HewittK.N., HillR.A., BoonW.C., JonesM.E., KovacicA., ZhouJ., and ClyneC.D. (2005). Estrogen—the good, the bad, and the unexpected. Endocr. Rev., 3, 322–30.
17.
WiggintonJ.G., PepeP.E., and IdrisA.H. (2010). Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients. Crit. Care Med., 10, Suppl., S620–S629.
18.
MorrisonB.3rd, ElkinB.S., DolleJ.P., and YarmushM.L. (2011). In vitro models of traumatic brain injury. Annu. Rev. Biomed. Eng.91–126.
19.
FoyM.R., XuJ., XieX., BrintonR.D., ThompsonR.F., and BergerT.W. (1999). 17beta-estradiol enhances NMDA receptor-mediated EPSPs and long-term potentiation. J. Neurophysiol., 2, 925–929.
20.
StoppiniL., BuchsP.A., and MullerD. (1991). A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods, 2, 173–182.
21.
MorrisonB., PringleA.K., McmanusT., EllardJ., BradleyM., SignorelliF., IannottiF., and SundstromL.E. (2002). L-arginyl-3,4-spermidine is neuroprotective in several in vitro models of neurodegeneration and in vivo ischaemia without suppressing synaptic transmission. Br. J. Pharmacol., 8, 1255–1268.
22.
SundstromL., MorrisonB., BradleyM., and PringleA. (2005). Organotypic cultures as tools for functional screening in the CNS. Drug Discov. Today, 14, 993–1000.
23.
ElkinB.S., and MorrisonB.3rd., (2007). Region-specific tolerance criteria for the living brain. Stapp Car Crash J.127–138.
24.
CaterH.L., GittermanD., DavisS.M., BenhamC.D., MorrisonB.3rd, and SundstromL.E. (2007). Stretch-induced injury in organotypic hippocampal slice cultures reproduces in vivo post-traumatic neurodegeneration: role of glutamate receptors and voltage-dependent calcium channels. J. Neurochem., 2, 434–447.
25.
YuZ., andMorrisonB.3rd., (2010). Experimental mild traumatic brain injury induces functional alteration of the developing hippocampus. J. Neurophysiol., 1, 499–510.
26.
HeuschkelM.O., FejtlM., RaggenbassM., BertrandD., and RenaudP. (2002). A three-dimensional multi-electrode array for multi-site stimulation and recording in acute brain slices. J. Neurosci. Methods, 2, 135–148.
27.
LamprechtM.R., and MorrisonB.3rd., (2014). GPR30 activation is neither necessary nor sufficient for acute neuroprotection by 17beta-estradiol after an ischemic injury in organotypic hippocampal slice cultures. Brain Res.131–137.
28.
RobertsonC.L. (2004). Mitochondrial dysfunction contributes to cell death following traumatic brain injury in adult and immature animals. J. Bioenerg. Biomembr., 4, 363–368.
29.
HaddadS.H., and ArabiY.M. (2012). Critical care management of severe traumatic brain injury in adults. Scand. J. Trauma Resusc. Emerg. Med.20, 12.
30.
HallH.I., SongR., RhodesP., PrejeanJ., AnQ., LeeL.M., KaronJ., BrookmeyerR., KaplanE.H., MckennaM.T., and JanssenR.S.; HIV Incidence Surveillance Group. (2008). Estimation of HIV incidence in the United States. JAMA, 5, 520–529.
31.
BrownC.M., SuzukiS., JelksK.A., and WiseP.M. (2009). Estradiol is a potent protective, restorative, and trophic factor after brain injury. Semin. Reprod. Med., 3, 240–249.
32.
ZlotnikA., LeibowitzA., GurevichB., OhayonS., BoykoM., KleinM., KnyazerB., ShapiraY., and TeichbergV.I. (2012). Effect of estrogens on blood glutamate levels in relation to neurological outcome after TBI in male rats. Intensive Care Med., 1, 137–44.
33.
DayN.L., FloydC.L., D'alessandroT.L., HubbardW.J., and ChaudryI.H. (2013). 17beta-estradiol confers protection following traumatic brain injury in the rat and involves activation of G protein-coupled estrogen receptor 1 (GPER). J. Neurotrauma, 30, 1531–1541.
34.
EmersonC.S., HeadrickJ.P., and VinkR. (1993). Estrogen improves biochemical and neurologic outcome following traumatic brain injury in male rats, but not in females. Brain Res., 1, 95–100.
35.
RoofR.L., and HallE.D. (2000). Estrogen-related gender difference in survival rate and cortical blood flow after impact-acceleration head injury in rats. J. Neurotrauma, 12, 1155–1169.
36.
CimarostiH., ZaminL.L., FrozzaR., NassifM., HornA.P., TavaresA., NettoC.A., and SalbegoC. (2005). Estradiol protects against oxygen and glucose deprivation in rat hippocampal organotypic cultures and activates Akt and inactivates GSK-3beta. Neurochem. Res., 2, 191–199.
37.
LiuR., WangX., LiuQ., YangS.H., and SimpkinsJ.W. (2007). Dose dependence and therapeutic window for the neuroprotective effects of 17beta-estradiol when administered after cerebral ischemia. Neurosci. Lett., 3, 237–241.
38.
SimpkinsJ.W., RajakumarG., ZhangY.Q., SimpkinsC.E., GreenwaldD., YuC.J., BodorN., and DayA.L. (1997). Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J. Neurosurg., 5, 724–730.
39.
SimpkinsJ.W., and SinghM. (2008). More than a decade of estrogen neuroprotection. Alzheimers Dement., 4, 1 Suppl. 1, S131–S136.
MathysM.L., MccarrellJ., SleeperR.B., and BlaszczykA.T. (2013). Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia. Ann. Pharmacother.47, e10.
42.
FrankiewiczT., PotierB., BashirZ.I., CollingridgeG.L., and ParsonsC.G. (1996). Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol., 4, 689–697.
43.
ParsonsC.G., DanyszW., and QuackG. (1999). Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data. Neuropharmacology, 6, 735–767.
44.
KoekW., WoodsJ.H., and WingerG.D. (1988). MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther., 3, 969–974.
45.
TaskerR.C., CoyleJ.T., and VornovJ.J. (1992). The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK-801. J. Neurosci., 11, 4298–4308.
46.
VornovJ.J., TaskerR.C., and CoyleJ.T. (1994). Delayed protection by MK-801 and tetrodotoxin in a rat organotypic hippocampal culture model of ischemia. Stroke, 2, 457–464; discussion 464–465.
47.
KutzingM.K., LuoV., and FiresteinB.L. (2012). Protection from glutamate-induced excitotoxicity by memantine. Ann. Biomed. Eng., 5, 1170–1181.
48.
BiegonA., FryP.A., PadenC.M., AlexandrovichA., TsenterJ., and ShohamiE. (2004). Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits. Proc. Natl. Acad. Sci. U. S. A., 14, 5117–5122.
49.
IkonomidouC., and TurskiL. (2002). Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol., 6, 383–386.
50.
StromJ.O., TheodorssonA., and TheodorssonE. (2011). Mechanisms of estrogens' dose-dependent neuroprotective and neurodamaging effects in experimental models of cerebral ischemia. Int. J. Mol. Sci., 3, 1533–1562.
51.
SmithC.C., and McmahonL.L. (2006). Estradiol-induced increase in the magnitude of long-term potentiation is prevented by blocking NR2B-containing receptors. J. Neurosci., 33, 8517–8522.
52.
LiuY., WongT.P., AartsM., RooyakkersA., LiuL., LaiT.W., WuD.C., LuJ., TymianskiM., CraigA.M., and WangY.T. (2007). NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci., 11, 2846–2857.
53.
ParsonsC.G., DanyszW., and QuackG. (1998). Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect., 9, 523–569.
